Levetiracetam Axcount

Levetiracetam, the active ingredient in Levetiracetam Axcount, is an antiepileptic presented as an oral tablet for systemic use. It is indicated for the treatment of partial, generalized tonic‑clonic and myoclonic seizures in both adult and pediatric patients.

GNH USA supplies Levetiracetam Axcount as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Our network ensures timely delivery and regulatory compliance across EU and other markets.

Levetiracetam is an antiepileptic drug that reduces neuronal excitability in seizure disorders.

- Partial seizures: reduces frequency of focal onset seizures. - Generalized tonic‑clonic seizures: helps control convulsive episodes. - Myoclonic seizures: diminishes rapid muscle jerks associated with the condition.

Levetiracetam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue - Dizziness - Somnolence - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions such as Stevens‑Johnson syndrome - Mood changes including depression or suicidal thoughts - Rash or skin eruptions - Blood dyscrasias (e.g., leukopenia, thrombocytopenia) - Respiratory depression - Multi‑organ hypersensitivity syndrome

When prescribing Levetiracetam, clinicians should consider several safety measures.

- Dose adjustment in renal impairment: assess creatinine clearance before prescribing. - Monitor psychiatric symptoms: watch for depression, anxiety or agitation. - Avoid abrupt discontinuation: taper under medical supervision to prevent seizure exacerbation. - Use cautiously in patients with hepatic dysfunction: limited data are available. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Concomitant use with carbamazepine: may reduce levetiracetam plasma levels. - Co‑administration with enzyme‑inducing antiepileptics (e.g., phenytoin, phenobarbital): may decrease efficacy. - Combination with strong CYP3A4 inhibitors (e.g., ketoconazole): limited data, monitor levels.

Moderate Interactions (Monitor Closely): - Concurrent use with other antiepileptics (e.g., valproate): may increase side‑effect risk. - Alcohol consumption: may enhance central nervous system depression. - Use with oral contraceptives: may slightly reduce contraceptive effectiveness.